REFERENCES

1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641-54.

2. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2020;27:217-22.

3. Kaku M, Berk JL. Neuropathy associated with systemic amyloidosis. Semin Neurol 2019;39:578-88.

4. Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004;63:129-38.

5. Koike H, Mouri N, Fukami Y, et al. Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. J Neurol Sci 2021;421:117305.

6. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.

7. Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci 2020; doi: 10.1007/s10072-020-04889-2.

8. Koike H, Misu K, Ikeda S, et al. Study Group for Hereditary Neuropathy in Japan. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002;59:1771-6.

9. Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 2021;268:2109-22.

10. Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res 2019;29:245-51.

11. Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 2019;15:387-404.

12. Karam C, Dimitrova D, Christ M, Heitner SB. Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis. Neurol Clin Pract 2019;9:309-13.

13. Mazzeo A, Russo M, Di Bella G, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in sicily, an Italian endemic area. J Neuromuscul Dis 2015;2:S39-48.

14. Saeki Y, Ueno S, Yorifuji S, Sugiyama Y, Ide Y, Matsuzawa Y. New mutant gene (transthyretin Arg 58) in cases with hereditary polyneuropathy detected by non-isotope method of single-strand conformation polymorphism analysis. Biochem Biophys Res Commun 1991;180:380-5.

15. Zólyomi Z, Benson MD, Halász K, Uemichi T, Fekete G. Transthyretin mutation (serine 84) associated with familial amyloid polyneuropathy in a Hungarian family. Amyloid 1998;5:30-4.

16. Murakami T, Tachibana S, Endo Y, et al. Familial carpal tunnel syndrome due to amyloidogenic transthyretin His 114 variant. Neurology 1994;44:315-8.

17. Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011;18:53-62.

18. Cortese A, Vegezzi E, Lozza A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 2017;88:457-8.

19. Lozeron P, Mariani LL, Dodet P, et al. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 2018;91:e143-52.

20. Théaudin M, Lozeron P, Algalarrondo V, et al. French FAP Network (CORNAMYL) Study Group. Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas. Eur J Neurol 2019;26:497-e36.

21. Adams D, Lozeron P, Theaudin M, et al. French Network for FAP. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012;19 Suppl 1:61-4.

22. Cappellari M, Cavallaro T, Ferrarini M, et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 2011;16:119-29.

23. Goyal NA, Mozaffar T. Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy: an ALS mimicker. Neurol Genet 2015;1:e18.

24. Planté-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-8.

25. Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012;45:26-31.

26. Dohrn MF, Röcken C, De Bleecker JL, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013;260:3093-108.

27. Mariani LL, Lozeron P, Théaudin M, et al. French Familial Amyloid Polyneuropathies Network (CORNAMYL) Study Group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015;78:901-16.

28. Ando Y, Ueyama H, Watanabe S, et al. Early involvement of motor nerve dysfunction in atypical cases with familial amyloidotic polyneuropathy (FAP) type I. Muscle Nerve 1993;16:978-9.

29. Yoshioka A, Yamaya Y, Saiki S, et al. A case of familial amyloid polyneuropathy homozygous for the transthyretin Val30Met gene with motor-dominant sensorimotor polyneuropathy and unusual sural nerve pathological findings. Arch Neurol 2001;58:1914-8.

30. Salvi F, Scaglione C, Michelucci R, et al. Atypical familial motor neuropathy in patients with mutant TTR Ile68Leu. Amyloid 2003;10:185-9.

31. Riboldi G, Del Bo R, Ranieri M, et al. Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation. Case Rep Neurol 2011;3:62-8.

32. Lozeron P, Lacroix C, Theaudin M, et al. An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation. Amyloid 2013;20:188-92.

33. Eldhagen P, Berg S, Lund LH, Sörensson P, Suhr OB, Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med 2021;289:895-905.

34. Guy CD, Jones CK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 2001;24:181-5.

35. Adams D, Suhr OB, Hund E, et al. European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016;29 Suppl 1:S14-26.

36. Cowan AJ, Skinner M, Berk JL, et al. Macroglossia - not always AL amyloidosis. Amyloid 2011;18:83-6.

37. Briani C, Cavallaro T, Ferrari S, et al. Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis. J Neurol 2012;259:2226-8.

38. Conceição I, González-Duarte A, Obici L, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2016;21:5-9.

39. Coutinho P, Martins da Silva A, Lopas LJ. . Forty years of experience with type 1 amyloid neuropathy. Review of 483 cases. In: Amyloid and amyloidosis. Amsterdam: Excerpta Medica;1980. p. 88-98.

40. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012;87:1196-201.

41. Joy T, Wang J, Hahn A, Hegele RA. Apoa1 related amyloidosis: a case report and literature review. Clin Biochem 2003;36:641-5.

42. Kiuru S, Seppäläinen AM. Neuropathy in familial amyloidosis , Finnish type (FAF): electrophysiological studies. Muscle Nerve 1994;17:299-304.

43. Boysen G, Galassi G, Kamieniecka Z, Schlaeger J, Trojaborg W. Familial amyloidosis with cranial neuropathy and corneal lattice dystrophy. J Neurol Neurosurg Psychiatry 1979;42:1020-30.

44. Sunada Y, Shimizu T, Nakase H, et al. Inherited amyloid polyneuropathy type IV (gelsolin variant) in a Japanese family. Ann Neurol 1993;33:57-62.

45. Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL Amyloidosis in Olmsted county, Minnesota, 1990 through 2015. Mayo Clin Proc 2019;94:465-71.

46. Zampieri M, Cappelli F, Allinovi M, et al. Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. Amyloid 2021;28:211-2.

47. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22.

48. Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 2011;18:604-10.

49. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32):45-59.

50. Vucic S, Chong PS, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve 2003;28:696-702.

51. Luigetti M, Papacci M, Bartoletti S, Marcaccio A, Romano A, Sabatelli M. AL amyloid neuropathy mimicking a chronic inflammatory demyelinating polyneuropathy. Amyloid 2012;19:53-5.

52. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001;248:647-57.

53. Falk RH, Skinner M. The systemic amyloidosis: an overview. Adv Intern Med 2000.

54. Blank N, Hegenbart U, Dietrich S, et al. Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid 2018;25:37-45.

55. Gaspar BL, Garg C, Vasishta RK, Nada R, Goyal MK. Localised SAA amyloidosis with intra-axonal intra-myelin amyloid deposits. Pathology 2017;49:103-5.

56. Maury CP. beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients. Rheumatol Int 1990;10:1-8.

57. Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 2012;366:2276-83.